COVID-19 - BioTuesdays

Markets

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...

March 15, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Markets

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...

February 18, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Markets

Maxim recalibrates biotech; lowering PTs as industry multiples contract

In an industry wide series of research reports, Maxim Group analyst Jason McCarthy, Ph.D., lowered price targets on stocks in his coverage universe, saying industry multiples have contracted but company outlooks remain...

February 2, 2022

Developments

Dyadic introduces novel method to produce synthetic cannabinoids

Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...

January 21, 2022

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Markets

Dawson James starts Bluejay Diagnostics at buy; PT $10

Dawson James Securities initiated coverage of Bluejay Diagnostics (NASDAQ:BJDX) with a “buy” rating and price target of $10. The stock closed at $2.74 on Jan. 11. Bluejay is focused on improving patient outcomes...

January 12, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Developments

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Needle-free injection company PharmaJet’s partner, Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine, ZyCoV-D, in Korea. The plan is to manufacture more than 80...

January 4, 2022

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021

Executive Moves

Ondine Biomedical appoints renowned Prof Trevor Jones to lead COVID-19 advisory board

Ondine Biomedical (LSE:OBI), appointed Prof. Trevor Jones, CBE FMedSci, to lead a new advisory board on the use of its pioneering photodisinfection-based technology to prevent and treat COVID-19. Ondine’s non-antibiotic...

December 15, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Markets

SVB Leerink cuts Spruce Biosciences to MP; PT to $5 from $35

SVB Leerink downgraded Spruce Biosciences (NASDAQ:SPRB) to “market perform” from “outperform” and slashed its price target to $5 from $35 after reviewing the company’s third quarter business update, speaking with...

November 16, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for...

November 12, 2021

Developments

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

RNA Disease Diagnostics (RNADD) secured an exclusive global license to a rapid ribonucleic acid-based molecular lateral flow assay (LFA) technology jointly owned by the University of Maryland, Baltimore (UMB) and the...

November 9, 2021

Developments

South Africa clears Phase 1 trial for Oramed oral COVID-19 vaccine

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) majority-owned subsidiary, Oravax Medical, received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in...

October 29, 2021

Markets

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

October 25, 2021

Subscribe